AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01142440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: * Dietary instructions~* Oral hygiene instructions: GC plaque indicator kit~* Antibacterial therapy: medident sol. one week a month, for 6 months~* Fluorides: VOCO Profluorid varnish, once every 3 month~* Restoration~* Follow ups
Study NCT02917343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mirror therapy and repetitive task training
Study NCT01142440 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: behavioral intervention
Description: * Dietary instructions~* Oral hygiene instructions: GC plaque indicator kit~* Antibacterial therapy: medident sol. one week a month, for 6 months~* Fluorides: VOCO Profluorid varnish, once every 3 month~* Restoration~* Follow ups
Study NCT01135472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Magnesium
Description: NEXIUM 40MG ONCE DAILY FOR 7 DAYS WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 40MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 80MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD.
Study NCT01711905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: daily dosage of 20 µg Vitamin D3 for 12 weeks
Study NCT01001936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-606
Study NCT01075113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT01075113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00411957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: ATV/r 300/100mg OD vs ATV/r 200/100 mg OD
Study NCT02918526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: airway management
Description: airway management with Laryngeal Mask or Oro Tracheal Intubation
Study NCT02918526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airway management
Description: airway management with Laryngeal Mask or Oro Tracheal Intubation
Study NCT00306163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: inhaled Ciclesonide 160 µg, once daily in the morning
Study NCT00306163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: inhaled Fluticasone 100 µg, twice daily
Study NCT04078438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neurofeedback augmentation
Description: Neurofeedback training was performed using a Neurocybernetics EEG Biofeedback system (Neurocybernetics Inc., Encino, CA, USA). The neurofeedback protocol was determined by the neurofeedback team, which included 3 psychiatrists, in consideration of the patient's main symptoms.~The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.~To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study.
Study NCT04078438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: The neurofeedback augmentation group and the medication-only group maintained the same medication use as that before the study.
Study NCT04078438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment as usual
Description: The neurofeedback augmentation group and the medication-only group maintained the same medication use as that before the study.
Study NCT04078438 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psychotherapy placebo sessions
Description: To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy.
Study NCT00402987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
Study NCT00402987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
Study NCT00402987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
Study NCT00402987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: dose 1 placebo followed 6-12 hours later by dose 2 placebo
Study NCT00003816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV
Study NCT02576002 — intervention group
Intervention type: DRUG
Intervention: Assigned pulmonary hypertension medication
Description: As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators
Study NCT01099605 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placement of a continuous infusion pump
Description: Each infusion pump is placed below the mucosa of the rectum. Infusion of either the drug or saline will continue for approximately 3-4 days.
Study NCT01099605 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous infusion pump of bupivacaine
Description: bupivacaine 0.25% at 4ml/hr for 3 to 4 days
Study NCT04015336 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 T-Cell Receptor (TCR)
Description: The dose of E7 T-Cell Receptor (TCR) T cells will be 3 x 10\^10 TCR+ T cells (unless fewer cells are generated) administered once.
Study NCT04070430 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 weeks of partial weight bearing on crutches
Description: Following surgery, patients will be instructed by their surgeon to use crutches for 2 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
Study NCT04070430 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 weeks of partial weight bearing on crutches
Description: Following surgery, patients will be instructed by their surgeon to use crutches for 4 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
Study NCT02692170 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Hepatitis B vaccine (20 μg)
Description: Investigational Product
Study NCT01115075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary fat/intake of carbohydrate
Description: Spontaneous intake of fat, carbohydrate, protein and alcohol each day for 17 days.
Study NCT01115075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spontaneous oscillations of dietary fat/intake of carbohydrate in relation to energy intake.
Description: Dietitians and senior level or graduate level dietetics students who are not restrained eaters to participate in food intake over 17 days. During this same time interval, integrated energy expenditure will be recorded using doubly-labeled water and day to day energy expenditure by accelerometer. Periodic blood sampling for leptin will be done completed at site intervals.
Study NCT02943018 — intervention group
Intervention type: OTHER
Intervention: anovaginal distance variation
Description: Kappa calculation
Study NCT05239364 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Catheter-based ablation of arrhythmias using radiofrequency.
Study NCT03649412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 Modified Release
Description: GSK2982772 MR will be available as MR prototype coated tablet with unit dose strength of 240 mg in Part A. In Part B, GSK2982772 MR prototype coated tablet with unit dose strength of 120 mg (may be changed following interim review of Part B) will be administered by subjects. GSK2982772 MR will be administered orally with 240 milliliter (mL) of water.
Study NCT03649412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 Immediate Release
Description: In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water
Study NCT04026685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine infusion
Description: continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure
Study NCT04026685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine infusion and Ringer-Acetate bolus
Description: continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure plus crystalloid Ringer-Acetate co-loading bolus of 1000 mL
Study NCT01524913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: 1 cc hyalgan to be injected into superior joint space
Study NCT01524913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: 1cc celestone (6 mg/cc) will be injected into the joint space
Study NCT01524913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringers
Description: 1 cc lactated ringers solution will be injected into the joint space
Study NCT02416011 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GENERIC
Description: The initial Stop Smoking for Good brochure, 10 Stop Smoking for Good booklets and 9 supportive My Story pamphlets delivered over 18 months, as used in our previous cessation study.
Study NCT02416011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eTARGET
Description: The product of Study I is expected to include the initial If You Vape brochure, a series of 10 If You Vape: Guide to Quitting Smoking booklets, distributed over 18 months, and 9 supportive My Story pamphlets, delivered in the months between booklets.
Study NCT01389466 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Step 1
Description: Investigational Product : MG1109 Dose : Cohort 1 : 0.125 mL Cohort 2 :0.25 mL Cohort 3 :0.5 mL Cohort 4 :1.0 mL intramuscularly injection, twice at an interval of 21 days
Study NCT00003816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study NCT00003816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00003816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT03195608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lane change assistance system
Description: This study will investigate the feasibility and preliminary efficacy of a 6-session lane change ADAS-intervention on the simulated driving performance of individuals with mild to moderate PD. We anticipate that the use of lane change assist technology will decrease the number of driving errors in individuals with PD. As this is a feasibility study, we will evaluate: -recruitment capability and sample characteristics - data collection methods, procedures, and outcome measures - acceptability and suitability of the lane change assist technology intervention - preliminary efficacy The outcomes of this study will inform the design of a larger study, should such large-scale study be warranted.
Study NCT03399721 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chordate S101
Description: Active treatment: The controller creates air-mediated kinetic oscillations with regulated pressure and frequency during a preset treatment time
Study NCT03399721 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Chordate S101 Placebo
Description: Placebo treatment: Placebo treatment is similar to active treatment, but with no oscillations. It is difficult to discern any difference between active and placebo treatment.
Study NCT00003816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00003816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT04149626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Sedation using dexmedetomidine (initial bolus dose followed by continuous infusion)
Study NCT04149626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Sedation using midazolam (initial bolus dose followed by continuous infusion)
Study NCT01389466 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Step 1
Description: Investigational Product : MG1109 Dose : Cohort 1 : 0.125 mL Cohort 2 :0.25 mL Cohort 3 :0.5 mL Cohort 4 :1.0 mL intramuscularly injection, twice at an interval of 21 days
Study NCT00003816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV
Study NCT00003816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV
Study NCT00003816 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Given twice daily for 3 days
Study NCT01677260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg metformin hydrochloride extended release caplet (test drug)
Description: In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
Study NCT01677260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg metformin hydrochloride prolonged release tablet (reference drug)
Description: In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
Study NCT04149626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Sedation using remifentanil (initial bolus dose followed by continuous infusion)
Study NCT05723302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MIP/MEP
Description: MIP/MEP
Study NCT03553602 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR Brachytherapy + EBRT + STAD
Description: HDR Brachytherapy implant: 2 fractions of 12 Gy to the prostate/ proximal SV.~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET- positive lesions.~6 months hormonal therapy(LHRH agonist and anti-androgen\[until end of radiotherapy\])
Study NCT03561155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot assisted treatment (Amadeo®)
Description: The protocol will consist of exercises as follows:~passive modality , passive/plus modality , assisted therapy and Balloon.
Study NCT03561155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: The protocol will consist of exercises as follow:~upper limb mobilization, facilitation of movements and active tasks. The exercises will be focused on improving muscle strength, finger extension and flexion and motor control
Study NCT04340154 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chimeric antigen receptor T cell
Description: CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In sequential CAR-T clinical trials, CAR-T cells will be given twice（anti-CD19 CAR-T first, then anti-CD22 CAR-T). All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR-T cell infusion to determine the disease status.
Study NCT01652313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: 1 mg/day, tablets for 7 days, orally
Study NCT01990742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care Team (PCTeam)
Description: Palliative care teams will be established and will round with residents in the intervention nursing homes.
Study NCT00751478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALO-01
Description: ALO-01 capsules
Study NCT03195608 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants will practice their driving on a driving simulator with feedback form a trained interventionist.
Study NCT00751478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MSIR
Description: immediate release morphine sulfate
Study NCT00751478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02589288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Infusion of ropivacaine 0.2%
Description: Postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
Study NCT02589288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automatic Intermittent Bolus of ropivacaine 0.2%
Description: Postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% every hour and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
Study NCT01631968 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cement without antibiotic.
Study NCT01631968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cement with erytromycin and colistin.
Study NCT03245918 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant Capsule 125 MG
Description: Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
Study NCT03245918 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant oral suspension 20 mg/mL
Description: Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asparaginase Erwinia chrysanthemi
Description: Given IV or IM
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia chrysanthemi
Description: Given IV or IM
Study NCT03914625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV
Study NCT01389466 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Step 2
Description: Investigational Product : MG1109 Dose : Cohort 1 :0.5 mL Cohort 2 :1.0 mL intramuscularly injection, twice at an interval of 21 days
Study NCT03596736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elbow Hemiarthroplasty
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT or IV
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given PO or IV
Study NCT03914625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO or IV
Study NCT03596736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Elbow Arthroplasty